Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
22.64
-0.15 (-0.66%)
Nov 20, 2024, 4:00 PM EST - Market closed
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $12.59M in the quarter ending August 31, 2024, a decrease of -31.84%. This brings the company's revenue in the last twelve months to $56.42M, down -17.76% year-over-year. In the fiscal year ending November 30, 2023, Nurix Therapeutics had annual revenue of $76.99M with 99.31% growth.
Revenue (ttm)
$56.42M
Revenue Growth
-17.76%
P/S Ratio
24.56
Revenue / Employee
$198,676
Employees
284
Market Cap
1.60B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.59B |
10x Genomics | 629.74M |
InMode | 423.75M |
Kiniksa Pharmaceuticals International, | 384.10M |
Certara | 372.80M |
Immunocore Holdings | 296.31M |
Dynavax Technologies | 260.81M |
Travere Therapeutics | 203.45M |
NRIX News
- 14 hours ago - Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewsWire
- 3 days ago - Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewsWire
- 21 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology - GlobeNewsWire